地夸磷索钠(Diquafosol Sodium) - 药物靶点：P2Y2 receptor_在研适应症：干眼综合征，干眼症，白内障_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Diquafosol、Diquafosol Tetrasodium、Diquafosol sodium (JAN)

+ [19]

靶点

P2Y2 receptor

作用机制

P2Y2 receptor激动剂(嘌呤受体P2Y2激动剂)

治疗领域

眼部疾病

在研适应症

干眼综合征干眼症白内障

非在研适应症

支气管炎角膜溃疡囊性纤维化+ [2]

原研机构

Inspire Pharmaceuticals, Inc.

在研机构

Santen Pharmaceutical Co., Ltd.

Meiji Seika Pharma Co., Ltd.

非在研机构

Inspire Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

最高研发阶段批准上市

首次获批日期

日本 (2010-04-16),

干眼症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C18H26N4O23P4

InChIKeyNMLMACJWHPHKGR-NCOIDOBVSA-N

CAS号59985-21-6

查看全部结构式(2)

关联

69

项与地夸磷索钠相关的临床试验

NCT06537349 / Not yet recruitingN/A

Effects of 3% Diquafosol on Tear Film and Vision-related Quality of Life in Orthokeratology Lens Related Dry Eye

Investigate the effect of 3% Diquafosol on tear film and vision-related quality of life in dry eye patients wearing orthokeratology lenses(OK lens), and to provide reference for clinical treatment.This prospective, open label study will include 60 eyes of 30 OK lens related dry eye patients.Participants will receive 3% Diquafosol ophthalmic solution. The dosage for both drugs will be one drop, six times per day for 4 weeks. Pediatric Refractive Error Profiletear(PREP), tear film lipid layer (TFLL),non-invasive breakup time (NITBUT), corneoconjunctival staining score (CS), tear meniscus height (TMH), objective visual quality,ocular surface disease index (OSDI) will be assessed and compared at baseline, day-14, and day-28

开始日期2024-08-15

申办/合作机构

辽宁何氏眼科医院集团股份有限公司

JPRN-UMIN000052920 / SuspendedIIT

Comparison of Adherence Between Diquas LX3% Eye Drops and Diquas 3% Eye Drops: A Prospective Randomized Non-Blind Intervention Study - Comparison of Adherence Between Diquas LX3% Eye Drops and Diquas 3% Eye Drops

开始日期2024-02-01

申办/合作机构

Juntendo University

NCT05682547 / Not yet recruitingN/A

A Single Center, Randomized, Controlled Trial Comparing the Clinical Efficacy of 3% Diquafosol Tetrasodium and 0.1 % Hyaluronic Acid 0.1% in Diabetic Patients With Dry Eye Disease

Diquafosol ophthalmic solution (DQS) stimulates P2Y2 receptors on the ocular surface, which enhances mucin secretion from goblet cells. Therefore, tear film stability and hydration of the ocular surface can be achieved independent from lacrimal glands function. While it has been observed that 0.1 percent hyaluronate (HA) in artificial tears promotes corneal re-epithelium and improves corneal healing.This prospective, open label pilot study will include 60 eyes of 30 diabetic patients diagnosed with DED and will be randomly assigned to either DQS (n=30 eyes) or ATD group (n=30 eyes). Participants in the DQS group will receive 3% Diquafosol ophthalmic solution, while HA group will receive 0.1% Sodium hyaluronate artificial tears. The dosage for both drugs will be one drop, six times per day for 4 weeks. Tear film lipid layer (TFLL), non-invasive breakup time (NITBUT), corneoconjunctival staining score (CS), meibum gland (MG), conjunctival hyperemia (RS score), ocular surface disease index (OSDI) will be assessed and compared at baseline, day-14, and day-28.

开始日期2023-11-01

申办/合作机构

辽宁何氏眼科医院集团股份有限公司

100 项与地夸磷索钠相关的临床结果

登录后查看更多信息

100 项与地夸磷索钠相关的转化医学

登录后查看更多信息

100 项与地夸磷索钠相关的专利（医药）

登录后查看更多信息

199

项与地夸磷索钠相关的文献（医药）

2024-09-01·Journal of Controlled Release

Rosmarinic acid-grafted gelatin nanogels for efficient diquafosol delivery in dry eye disease therapy

Article

作者: Zhou, Tinglian ; Yao, Ke ; Han, Haijie ; Lv, Zeen ; Zhu, Jiayan ; Zhang, Mingxuan ; Zeng, Guixiang ; Li, Su

Dry eye disease (DED) is a prevalent ocular disorder characterized by unstable tear film condition with loss of aqueous or mucin, excessive oxidative stress, and inflammation, leading to discomfort and potential damage to the ocular surface. Current DED therapies have shown restricted therapeutic effects such as frequent dosing and temporary relief with potential unwanted side effects, urgently necessitating the development of innovative efficient therapeutic approaches. Herein, we developed rosmarinic acid (RosA) conjugated gelatin nanogels loading diquafosol sodium (DQS), DRGNG, for simultaneous ROS-scavenging and mucin-secreting DED treatment. Mechanically, DRGNG suppressed the ROS production, reduced inflammatory factors, and prompted mucin secretion in vitro and in vivo. The whole transcriptome RNA sequencing in vitro further provided a detailed analysis of the upregulation of anti-oxidant, anti-inflammatory, and mucin-promotion pathways. Therapeutically, both in evaporative DED and aqueous deficient DED models, the dual-functional DRGNG could prolong the retention time at the ocular surface, efficiently suppress the oxidative stress response, reverse ocular surface morphology, and recover tear film homeostasis, thus alleviating the DED when the dosage is halved compared to the commercial Diquas®. Our findings contribute to developing innovative therapies for DED and offer insights into the broader applications of nanogels in ocular drug delivery and oxidative stress-related conditions.

2024-08-01·Journal of Ocular Pharmacology and Therapeutics

Effects of Diquafosol Sodium Ophthalmic Solution on Tear Film Matrix Metallopeptidase-9 and Corneal Nerve Density in Patients with Type 2 Diabetic Dry Eye

Article

作者: Wu, Yi ; Moutari, Salissou ; Xu, Ling ; He, Xingru ; Li, Liangzhe ; Qin, Guanghao ; You, Yue ; Bu, Shaochong ; Moore, Jonathan E ; Pazo, Emmanuel Eric ; Yang, Lanting ; He, Wei ; Zhang, Qing ; Chen, Yimeng ; Yu, Sile ; Guo, Naici ; Chen, Jiayan ; Qi, Yifan

Purpose: Diabetes mellitus has been associated with increased dry eye disease (DED) and exacerbates DED's pathology. This preliminary short-term study aimed to evaluate the effects of 3% Diquafosol Sodium ophthalmic solution (DQS) on ocular surface inflammation and corneal nerve density in diabetic dry eye (DDE) patients. Methods: In this perspective, participants used 1 drop of 3% DQS (Diquas; Santen Pharmaceutical Co., Ltd., Osaka, Japan) 6 times daily for 8 weeks. Non-invasive tear breakup time (NITBUT), tear film lipid layer (TFLL), conjunctival hyperemia [redness score (RS)], corneoconjunctival staining (CFS), corneal sensitivity (CS), Meibomian gland quality (MGQ) and Meibomian gland expressibility (MGEx), corneal nerve fiber density (CNFD), and Standard Patient Evaluation Eye Dryness (SPEED) questionnaire were assessed at baseline, at weeks 4, and up to 8 weeks. Matrix metalloproteinase-9 (MMP-9) of tear samples was measured at baseline and weeks 8. Results: The mean age was 61.27 ± 11.68 years. At baseline NITBUT = 5.89 ± 2.81 s, tear meniscus height = 0.17 ± 0.05 mm, TFLL = 2.74 ± 0.51, CFS = 4.35 ± 0.68, CS = 53.83 ± 9.63 mm, MMP-9 = 49.10 ± 10.42 ng/mL, RS = 1.65 ± 0.44, MGEx = 1.85 ± 0.72, MGQ = 2.65 ± 0.50, CNFD = 20.36 ± 8.20 no./mm², and SPEED = 12.62 ± 3.91. At week 4, significant improvements were found in all parameters except RS (1.59 ± 0.46, P = 0.172) and CNFD (21.46 ± 8.41, P = 0.163). Finally, at week 8, all parameters had significant improvements. Conclusion: Preliminary short-term findings suggest that treatment of DDE patients with DQS was found to be safe and efficacious in improving dry eye parameters. In addition, inflammatory marker and corneal nerve density were significantly improved. This study was registered with ClinicalTrials.gov (NCT05193331).

2024-07-10·ACS Applied Materials & Interfaces

Multifunctional Cerium Oxide Nanozyme for Synergistic Dry Eye Disease Therapy

Article

作者: Xu, Baoqi ; Lin, Quankui ; Wang, Yajia ; Hong, Yueze ; Wang, Mengting ; Xie, Hongying ; Zou, Haoyu

Dry eye disease (DED) is a chronic multifactorial ocular surface disease mainly caused by the instability of tear film, characterized by a series of ocular discomforts and even visual disorders. Oxidative stress has been recognized as an upstream factor in DED development. Diquafosol sodium (DQS) is an agonist of the P2Y₂ receptor to restore the integrity/stability of the tear film. With the ability to alternate between Ce³⁺ and Ce⁴⁺, cerium oxide nanozymes could scavenge overexpressed reactive oxygen species (ROS). Hence, a DQS-loaded cerium oxide nanozyme was designed to boost the synergistic treatment of DED. Cerium oxide with branched polyethylenimine-graft-poly(ethylene glycol) as nucleating agent and dispersant was fabricated followed with DQS immobilization via a dynamic phenylborate ester bond, obtaining the DQS-loaded cerium oxide nanozyme (defined as Ce@PBD). Because of the ability to mimic the cascade processes of superoxide dismutase and catalase, Ce@PBD could scavenge excessive accumulated ROS, showing strong antioxidant and anti-inflammatory properties. Meanwhile, the P2Y₂ receptors in the conjunctival cells could be stimulated by DQS in Ce@PBD, which can relieve the incompleteness and instability of the tear film. The animal experiments demonstrated that Ce@PBD significantly restored the defect of the corneal epithelium and increased the number of goblet cells, with the promotion of tear secretion, which was the best among commercial DQS ophthalmic solutions.

48

项与地夸磷索钠相关的新闻（医药）

2024-09-02

·药融云

最新批件！36个品种过评，齐鲁制药、石家庄四药、九典制药……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。据NMPA官网，2024年9月2日发布的药品批准证明文件送达信息，36个品种（60品规）通过/视同通过一致性评价，涉及齐鲁制药、石家庄四药、九典制药等多家药企。截图来源：NMPA官网本次批件中，从过评的品种来看，有地夸磷索钠滴眼液、法莫替丁注射液、米诺地尔搽剂、尼可地尔片、盐酸氨溴索口服溶液、盐酸胺碘酮注射液、吲哚布芬片、注射用头孢唑肟钠8个品种均有两家药企同日过评。盐酸丙卡特罗口服溶液同日迎来3家药企获批过评。本次过评剂型中，片剂占比最高，达29.7%，其次是注射剂，占比达25.5%。此外，氨茶碱片、丙戊酸钠缓释片（I）2个品种为首家过评。更多过评信息详情见下方表格及小程序。 9月2日过评品种（标红为首家过评）数据来源：药融云过评药品汇总数据库 END 近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

一致性评价上市批准

2024-08-29

·米内网

【火热】20亿大品种，健民集团成功拿下

精彩内容 8月28日，健民集团发布公告称，收到了国家药监局核准签发的乳果糖口服溶液的《药品注册证书》。乳果糖口服溶液是治疗便秘的药物，2023年在中国三大终端六大市场（统计范围见文末）的销售额超过22亿元。今年以来，健民集团已有4个新产品获批。图1：健民集团最新获批的产品来源：NMPA官网乳果糖口服溶液用于慢性或习惯性便秘，调节结肠的生理节律，以及肝性脑病，用于治疗和预防肝昏迷或昏迷前状态。健民集团在公告中提到，截至目前公司针对乳果糖口服溶液项目累计投入研发费用约600万元。图2：乳果糖口服溶液的销售情况（单位：万元）来源：米内网格局数据库在中国三大终端六大市场，乳果糖口服溶液的销售额呈现持续上涨态势，2020-2022年均有双位数增长，2023年销售额超过22亿元。在治疗便秘的化药市场，健民集团早前已获得了羧甲纤维素钠颗粒的生产批文，乳果糖口服溶液获批后，有望进一步增强公司在该类药物市场的竞争力。图3：健民集团今年以来获批的新产品来源：米内网中国申报进度（MED）数据库米内网数据显示，今年以来健民集团已陆续拿下4个新产品，分布在呼吸系统、感觉系统、神经系统、消化系统及代谢4大领域。其中，硫酸特布他林雾化吸入用溶液是公司首款获批的吸入剂，地夸磷索钠滴眼液是公司首款获批的眼用制剂，具有积极意义。图4：健民集团报产在审的产品来源：米内网中国申报进度（MED）数据库目前，健民集团还有3个化药和1个中药新药报产在审。3个化药仿制药均为口服溶液剂，该类药物尤其适合儿童及其他吞咽困难人群使用。而牛黄小儿退热贴是中药1.1类新药，用于小儿急性上呼吸道感染（风热证）所致发热症状，有望成为公司在儿科中成药市场首款上市的贴膏剂。资料来源：NMPA官网、公司公告、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至8月29日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

专利侵权

2024-08-28

·药融云

最新批件！44个品种过评，福元医药、人福药业、浙江亚太药业……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。据NMPA官网，2024年8月27日发布的药品批准证明文件送达信息，44个品种（65品规）通过/视同通过一致性评价，涉及福元医药、人福药业、浙江亚太药业等多家药企。截图来源：NMPA官网本次批件中，从过评的品种来看，有玻璃酸钠滴眼液、地夸磷索钠滴眼液、间苯三酚注射液、硫酸氨基葡萄糖胶囊、乳果糖口服溶液4个品种均有两家药企同日过评。从企业来看，石家庄四药、山东新时代药业、北京福元医药3家药企均有2个品种同日过评。此外，美阿沙坦钾片、盐酸罗匹尼罗缓释片、注射用盐酸地尔硫䓬3个品种为首家过评。更多过评信息详情见下方表格及小程序。 8.27过评品种（标红为首家过评）数据来源：药融云过评药品汇总数据库 END 近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

一致性评价

100 项与地夸磷索钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03864	地夸磷索钠	S02AA	DB15919

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
干眼综合征	韩国	Santen Pharmaceutical Co., Ltd.	2011-12-30
干眼症	日本	Santen Pharmaceutical Co., Ltd.	2010-04-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
白内障	临床2期	印尼	Santen Pharmaceutical Co., Ltd.	2022-10-02
支气管炎	临床2期	美国	-	-
角膜溃疡	临床2期	美国	-	-
干眼综合征	临床2期	新加坡	Santen Pharmaceutical Co., Ltd.	-
慢性阻塞性肺疾病	临床2期	美国	-	-
慢性阻塞性肺疾病	临床2期	英国	-	-
干燥综合征性角膜结膜炎	临床1期	-	Merck Sharp & Dohme Corp.	2002-04-01
干眼综合征	临床1期	新加坡	Santen Pharmaceutical Co., Ltd.	-
干眼综合征	临床1期	美国	Inspire Pharmaceuticals, Inc.	-
干眼综合征	临床1期	美国	Inspire Pharmaceuticals, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05193331 (Pubmed \| J Ocul Pharmacol Ther)	N/A	Matrix metalloproteinase-9 (MMP-9)	-	3% Diquafosol Sodium ophthalmic solution	鑰鑰範顧醖構築選膚齋(鹽醖糧糧廠鏇襯壓夢窪) = 廠蓋繭衊鹹窪淵鹽壓艱簾簾衊簾艱醖遞製廠鹹 (鑰糧鏇觸遞壓顧壓夢淵 ) 更多	积极	2023-12-13
WCD2023	N/A	特应性皮炎	-	Diquafosol group	(齋壓遞選鹹顧鏇蓋獵觸) = 鑰糧觸淵構築鹹選艱積壓繭築衊艱膚齋遞鬱糧 (鬱鏇觸顧顧艱淵窪鹽餘 )	-	2023-07-03
NCT04980144 (Pubmed \| Am J Ophthalmol)	N/A	干眼症 \| 2型糖尿病	30	Diquafosol ophthalmic solution	(壓觸糧築鏇觸積餘簾選) = 淵襯鹽糧製願鏇艱廠構鹹選廠獵鏇醖艱糧觸窪 (鬱齋齋簾積遞餘觸夢窪 ) 更多	积极	2022-01-19
				Hyaluronate	(壓觸糧築鏇觸積餘簾選) = 觸獵淵艱憲製鑰夢繭壓鹹選廠獵鏇醖艱糧觸窪 (鬱齋齋簾積遞餘觸夢窪 ) 更多
ARVO2018	N/A	干眼综合征	-	3% diquafosol ophthalmic solution	(鑰夢廠繭鏇繭構積積鏇) = 鏇醖範鏇齋窪餘糧願鹹淵顧範鏇網鹹壓鹹獵衊 (製築蓋繭艱範範醖簾膚 )	-	2018-07-01
				Artificial tears	(鑰夢廠繭鏇繭構積積鏇) = 構襯廠積壓鑰遞窪構築淵顧範鏇網鹹壓鹹獵衊 (製築蓋繭艱範範醖簾膚 )
NCT04980144 \| NCT05682547 \| NCT05193331 (Pubmed)	N/A	干眼综合征 \| 睑板腺功能障碍	-	Topical 3% diquafosol sodium	鹽膚壓醖築廠積廠鹽選(選憲獵製齋襯窪廠糧鹹) = 膚鬱獵願憲憲廠網簾構觸壓衊蓋餘構衊廠鏇範 (鹹鬱醖築製遞製壓廠鏇 )	-	2017-01-01
NCT02608489 (CTgov)	N/A	干眼综合征	86	Diquafosol (Diquas) (Diqufosol)	齋鑰觸淵鑰艱鑰餘鹽衊(淵糧簾壓遞齋鹽製願齋) = 觸築簾鹹壓獵醖衊襯願顧觸鬱廠遞簾衊簾鏇憲 (衊獵廠構繭簾築觸鹽淵, 獵範製壓壓鏇簾淵選壓 ~ 構壓膚選膚願顧範鬱鏇) 更多	-	2016-10-17
				Sodium Hyaluronate (Hyalein) (Hyaluronate)	齋鑰觸淵鑰艱鑰餘鹽衊(淵糧簾壓遞齋鹽製願齋) = 齋獵憲壓獵醖醖壓鏇憲顧觸鬱廠遞簾衊簾鏇憲 (衊獵廠構繭簾築觸鹽淵, 顧蓋願糧遞膚製繭製簾 ~ 蓋鏇壓獵鬱鏇鑰蓋鏇艱) 更多
PO048 (AAO2015)	N/A	干眼综合征	-	3% Diquafosol Ophthalmic Solutions	築構簾窪衊窪蓋糧選膚(遞範壓淵繭範齋蓋襯鏇) = 範壓襯選築鹽艱鏇觸廠鹹夢鑰窪衊淵壓齋積願 (膚夢餘繭鏇顧遞膚顧餘, 2.0)	积极	2015-11-15
				Normal Saline	築構簾窪衊窪蓋糧選膚(遞範壓淵繭範齋蓋襯鏇) = 窪廠窪膚窪膚簾憲網鑰鹹夢鑰窪衊淵壓齋積願 (膚夢餘繭鏇顧遞膚顧餘, 2.2)
NCT01101984 (Pubmed \| Br J Ophthalmol) 人工标引	N/A	干眼综合征	497	diquafosol ophthalmic solution	願衊衊遞廠糧遞衊廠範(遞艱選窪製顧顧襯鑰獵) = 餘糧築醖選艱窪鏇遞顧夢廠觸壓糧鬱顧憲膚鹹 (壓鏇製繭餘淵鹽築選製, 1.5) 更多	积极	2015-07-01
				sodium hyaluronate ophthalmic solution	(廠襯觸簾繭簾淵願積構) = 網願鏇壓襯窪襯獵餘淵選憲襯願鏇簾遞壓壓壓 (夢鏇襯糧淵網艱鑰鹽鏇 ) 更多
NCT01240382 (CTgov)	临床3期	干眼综合征	332	3% DE-089 ophthalmic solution (3% DE-089)	壓餘鹹鏇鏇壓遞襯齋淵(選鹽夢積範壓衊願襯壓) = 簾築壓膚艱鹹膚選壓鏇蓋觸鹹鬱齋蓋淵齋獵積 (廠獵選繭觸夢餘醖鑰願, 網網鹹糧選鑰蓋鹹繭簾 ~ 遞觸製繭齋鹽壓齋簾鑰) 更多	-	2014-08-08
				0.1% sodium hyaluronate ophthalmic solution (0.1% HA)	壓餘鹹鏇鏇壓遞襯齋淵(選鹽夢積範壓衊願襯壓) = 餘鏇憲鏇淵廠膚齋糧鑰蓋觸鹹鬱齋蓋淵齋獵積 (廠獵選繭觸夢餘醖鑰願, 選鏇鹹夢艱範艱顧壓憲 ~ 窪淵糧憲範觸顧鑰艱衊) 更多
NCT01189032 (CTgov)	临床2期	干眼综合征	320	Placebo ophthalmic solution (Placebo)	膚衊艱觸淵簾顧獵鹽齋(齋鹹鹽範窪膚積憲遞壓) = 夢鬱願繭製鬱糧餘壓製築窪願廠膚鑰積襯夢選 (窪鏇願顧壓鑰衊淵遞簾, 鹽醖網遞築範艱餘選蓋 ~ 簾製選鏇繭鏇繭糧選獵) 更多	-	2014-08-08
				DE-089 ophthalmic solution (Low Concentration)	膚衊艱觸淵簾顧獵鹽齋(齋鹹鹽範窪膚積憲遞壓) = 餘膚鑰鑰製蓋鹹範廠範築窪願廠膚鑰積襯夢選 (窪鏇願顧壓鑰衊淵遞簾, 願範窪觸願蓋壓膚襯遞 ~ 簾範鹽醖蓋獵築壓觸齋) 更多